Whispers from the peptide communities.

Creatine and dendritic cells: what the UCLA paper found, and what the viral thread added

A September 2026 thread claimed a new UCLA study showed creatine activates dendritic cells and that depleting those cells abolished the anti-tumour effect. That depletion experiment is not in the paper — the word never appears. The real study injected creatine intraperitoneally with no oral arm, used a whole-body rather than immune-specific knockout, and tested human cells at roughly 500 times supplemented plasma levels. Meanwhile two independent papers report creatine promoting metastasis, one with hyperactive platelets in healthy human volunteers; the only randomised trial in cancer patients (n=263) was null on its primary endpoint and on survival; and an SLC6A8 inhibitor is in human oncology trials on the opposite thesis.

Five injuries BPC-157 healed — in rats. And the dihexa papers nobody mentioned were retracted

BPC-157 took over the week: mentions rose 44%, and the biggest post of the week listed five injuries it healed — a severed Achilles, a crushed spinal cord, a knee ligament, an eyeball, a section of bone. All five trace to real published studies. Four are rats, one is rabbits, none is human, and the post doesn't say so. More seriously, a large account told its audience dihexa 'has good humans safety data' — it has none, and the three papers establishing its proposed mechanism were retracted in April 2025 for image manipulation. Meanwhile the first adequately powered BPC-157 trial, with an MRI endpoint, quietly started recruiting.

Can you legally buy retatrutide? No — and the import alert isn't what people think

No. Retatrutide is not approved in any country, and as of September 2026 no marketing application has even been filed — Lilly has indicated a first-quarter 2027 submission. There is no legal route to obtain it outside a clinical trial, and unlike compounded semaglutide there was never an arguable shortage-based justification, because there is no approved product to be in shortage. Two things are widely misread: its appearance on an FDA import alert in August 2026 is a manufacturing-quality exclusion from automatic detention, not an approval; and the phase 3 results people quote describe pharmaceutical-grade compound at controlled doses.

Compounded GLP-1s: 503A, 503B and why the shortage route closed

Compounded semaglutide and tirzepatide were never a permanent category. They existed because both drugs were on the FDA shortage list, and US law permits compounding a copy of an approved drug only while a shortage lasts. Both shortages are resolved — tirzepatide since 19 December 2024, semaglutide since 21 February 2025 — and the grace periods ran out in spring 2025. Compounders sued twice and lost both times. In April 2026 the FDA proposed removing all three GLP-1s from the list of substances outsourcing facilities may compound from bulk at all.

GLP-1s and contraception: tirzepatide and semaglutide carry opposite warnings

Tirzepatide and semaglutide carry opposite warnings, and almost every article on this subject blurs them together. Tirzepatide can reduce absorption of oral contraceptives, and its label requires switching to a non-oral method or adding a barrier method for four weeks after starting and four weeks after every dose increase. Semaglutide carries no contraceptive warning at all — the interaction was studied and found not clinically relevant. Reverse that for pregnancy planning: semaglutide labels advise stopping at least two months before a planned pregnancy, while tirzepatide labels specify no washout period.

Tesamorelin cannot give you abs, and the reason is anatomical

The most-shared peptide result of the week was a user reporting visible abdominal definition after eight weeks of tesamorelin, without training or changing their diet. Tesamorelin does not do that, and the reason is anatomical rather than a matter of degree. It reduces visceral fat, which sits inside the peritoneal cavity behind the abdominal muscles. Visible definition is governed by subcutaneous fat, which sits on top of them. Tesamorelin's own FDA label reports no effect on subcutaneous adipose tissue.

Peptides in Iberia: Portugal has Europe's harshest possession rule, and almost nobody says so

Portugal has the harshest possession provision we have found anywhere in Europe. Article 57 of Lei n.º 81/2021 punishes anyone who buys, imports, transports or unlawfully holds a substance on the prohibited list with one to five years' imprisonment — with no quantity threshold of any kind. Germany sets milligram thresholds; Denmark and Norway cap penalties at two years and six months. Portugal sets no threshold and goes to five. And INFARMED does not authorise personal importation at all.

Peptides in Germany, Austria and Switzerland: the 1.5 mg threshold nobody mentions

Germany publishes exact milligram thresholds above which possessing a doping substance becomes a crime. For most growth-hormone peptides those numbers are generous — 150 mg for secretagogues, 180 mg for GHRH analogues. For one category they are not. The threshold for growth hormone releasing peptides is 1.5 mg, a hundredth of the others, and a single research vial will usually exceed it. That hundredfold gap sits inside one section of one annex, and it is the thing a German reader is least likely to know.